J0221 Lumizyme injection
Also known as: lumizyme, alglucosidase alfa
Lumizyme injection, a recombinant enzyme replacement therapy for Pompe disease.
In Plain Language
muscle disease enzyme treatment; Pompe disease therapy
Clinical Context
Intravenous enzyme replacement for Pompe disease. Provides recombinant human acid alpha-glucosidase enzyme activity.
RVU Information
CPT J0221 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J0221?
CPT J0221 (Lumizyme injection) is a J Codes (Drugs) code. Lumizyme injection, a recombinant enzyme replacement therapy for Pompe disease.
How is J0221 administered?
CPT J0221 is administered by a healthcare provider, typically via injection or infusion. Intravenous enzyme replacement for Pompe disease. Provides recombinant human acid alpha-glucosidase enzyme activity. It is used by Genetics, Neurology, Internal Medicine.
When is CPT J0221 used?
Intravenous enzyme replacement for Pompe disease. Provides recombinant human acid alpha-glucosidase enzyme activity.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.